8-K: Intuitive Reports Strong Q4 2025 Earnings, Da Vinci Growth

Intuitive announced robust fourth-quarter 2025 financial results, driven by significant growth in da Vinci procedures and system placements, alongside a positive outlook for 2026 despite anticipated procedure growth deceleration.

Summary

• Worldwide procedures (da Vinci and Ion combined) grew approximately 18% in Q4 2025 compared to Q4 2024.
• Da Vinci procedures increased by approximately 17%, while Ion procedures grew by approximately 44% in Q4 2025.
• The Company placed 532 da Vinci surgical systems in Q4 2025, up from 493 in Q4 2024, including 303 da Vinci 5 systems (compared to 174 in Q4 2024).
• Ion endoluminal system placements were 42 in Q4 2025, a decrease from 69 in Q4 2024.
• The da Vinci surgical system installed base reached 11,106 systems as of December 31, 2025, a 12% increase from 9,902 systems as of December 31, 2024.
• The Ion endoluminal system installed base grew to 995 systems as of December 31, 2025, a 24% increase from 805 systems as of December 31, 2024.
• Fourth quarter 2025 revenue was $2.87 billion, an increase of 19% compared to $2.41 billion in Q4 2024.
• Q4 2025 GAAP net income attributable to Intuitive was $795 million, or $2.21 per diluted share, up from $686 million, or $1.88 per diluted share, in Q4 2024.
• Q4 2025 non-GAAP net income attributable to Intuitive was $914 million, or $2.53 per diluted share, compared to $805 million, or $2.21 per diluted share, in Q4 2024.
• Full year 2025 total revenue reached $10.06 billion, up from $8.35 billion in 2024.
• Full year 2025 GAAP net income attributable to Intuitive Surgical, Inc. was $2.86 billion, or $7.87 per diluted share, compared to $2.32 billion, or $6.42 per diluted share, in 2024.
• The Company ended Q4 2025 with $9.03 billion in cash, cash equivalents, and investments, an increase of $0.60 billion during the quarter.

Sentiment

Score: 8

Explanation: The filing indicates strong financial performance with significant growth in revenue, net income, and procedure volumes for both Q4 and the full year 2025. The installed base for both da Vinci and Ion systems expanded considerably. While Ion system placements saw a quarterly decline and 2026 procedure growth is projected to decelerate, the overall outlook remains positive, supported by a robust cash position and continued market leadership.

Positives

• Worldwide procedures grew approximately 18% in Q4 2025, indicating strong demand for robotic-assisted surgery.
• Da Vinci procedures increased by 17% and Ion procedures by 44% in Q4 2025, demonstrating robust utilization of both key platforms.
• Da Vinci system placements increased to 532 in Q4 2025 from 493 in Q4 2024, with a significant rise in da Vinci 5 system placements (303 vs 174).
• The installed base for da Vinci systems grew 12% to 11,106, and Ion systems grew 24% to 995, indicating expanding market penetration and recurring revenue potential.
• Fourth quarter 2025 revenue increased by 19% to $2.87 billion, driven by procedure volume and system placements.
• GAAP net income attributable to Intuitive grew to $795 million ($2.21 diluted EPS) in Q4 2025 from $686 million ($1.88 diluted EPS) in Q4 2024, representing strong profitability.
• Non-GAAP net income attributable to Intuitive increased to $914 million ($2.53 diluted EPS) in Q4 2025 from $805 million ($2.21 diluted EPS) in Q4 2024.
• Instruments and accessories revenue increased by 17% to $1.66 billion in Q4 2025, reflecting high utilization of existing systems.
• The Company maintains a strong cash position with $9.03 billion in cash, cash equivalents, and investments as of December 31, 2025.

Negatives

• Ion endoluminal system placements decreased to 42 in Q4 2025 from 69 in Q4 2024, indicating a slowdown in new system adoption for this platform.
• The 2026 financial outlook projects worldwide da Vinci procedure growth of approximately 13% to 15%, which is a deceleration compared to the 18% growth experienced in 2025.
• The Company anticipates an estimated impact from tariffs of 1.2% of revenue on its non-GAAP gross profit margin in 2026, with potential for material additional impact if tariffs change.

Risks

• The overall macroeconomic environment may impact customer spending and the Company's costs, including tariffs, inflation, and interest rates.
• Geopolitical conflicts, such as those between Ukraine and Russia and in the Middle East, could disrupt operations.
• Disruptions to the Company's supply chain, including difficulties in obtaining a sufficient supply of materials, pose a risk.
• Hospitals may curtail or delay capital spending, affecting system placements.
• Global and regional economic and credit market conditions could impact healthcare spending.
• Delays in obtaining new product approvals, clearances, or certifications from regulatory authorities (e.g., U.S. FDA) could hinder market access.
• The Company faces risks of inability to comply with complex FDA and other regulations, potentially leading to significant enforcement actions.
• Healthcare reform legislation in the U.S. could impact hospital spending, reimbursement, and fees on medical device revenues.
• Changes in hospital admissions and actions by payers to limit or manage surgical procedures could affect procedure volumes.
• The timing and success of product development and customer acceptance of new products are uncertain.
• The results of collaborations, in-licensing arrangements, joint ventures (e.g., with Shanghai Fosun Pharmaceutical), strategic alliances, or partnerships may not meet expectations.
• The Company faces risks associated with its ability to successfully integrate acquisitions.
• Intellectual property positions and litigation could result in adverse outcomes.
• Risks are associated with the Company's operations and any expansion outside of the U.S.
• Unanticipated manufacturing disruptions or the inability to meet demand for products could occur.
• Reliance on soleand single-sourced suppliers creates vulnerability.
• Adverse publicity regarding the Company and the safety of its products or adequacy of training could harm its reputation.
• Changes to tax legislation, guidance, and interpretations could impact financial results.
• Changes in tariffs, trade barriers, and regulatory requirements (including U.S. tariffs on imports from Mexico, Germany, and China) could materially affect financial results.

Future Outlook

For the full year 2026, Intuitive expects worldwide da Vinci procedure growth of approximately 13% to 15%, a deceleration from 18% in 2025. Non-GAAP gross profit margin is projected to be between 67% and 68% of revenue, including an estimated 1.2% impact from tariffs. Non-GAAP operating expense growth is anticipated to be 11% to 15% in 2026, compared to 12% in 2025. The Company warns that additional tariffs or modifications to existing tariffs could materially impact financial results.

Industry Context

Intuitive continues to demonstrate strong leadership in the robotic-assisted surgery market, with robust growth in its flagship da Vinci platform and significant expansion of its installed base. The strong procedure growth reflects the increasing adoption of minimally invasive surgical techniques globally. While the Ion system's new placements saw a quarterly dip, its procedure volume growth indicates increasing utilization. The company's performance aligns with the broader trend of healthcare innovation focusing on less invasive procedures and advanced surgical technologies.

Stakeholder Impact

• Shareholders are positively impacted by strong financial results, including increased revenue, net income, and EPS, as well as a growing installed base and robust cash position.
• Customers (hospitals and healthcare providers) benefit from the continued innovation and expansion of da Vinci and Ion systems, supporting advanced minimally invasive care.
• Employees are impacted by share-based compensation arrangements and the Company's contribution to the Intuitive Foundation.
• Suppliers may see continued demand for components and materials due to increased system placements and procedure volumes, though supply chain disruptions remain a risk.

Next Steps

• Intuitive will hold a teleconference on January 22, 2026, at 1:30 p.m. PDT to discuss the fourth quarter 2025 financial results.
• A webcast replay of the call will be made available on Intuitive's website (www.intuitive.com) within 24 hours after the live teleconference and will be accessible for at least 30 days.

Key Dates

Recommendation

Intuitive's Q4 and full-year 2025 results demonstrate exceptional financial health and operational strength, marked by significant revenue and earnings growth, expanding installed bases, and robust procedure volumes across its core platforms. Despite a projected deceleration in da Vinci procedure growth for 2026 and a dip in Ion system placements, the company maintains a dominant market position in robotic-assisted surgery, a strong balance sheet with substantial cash reserves, and a clear path for continued innovation. The long-term growth drivers in minimally invasive care remain intact, making ISRG a compelling 'strong buy' for investors seeking exposure to a market leader with consistent performance and future potential.

Keywords

Robotic-assisted surgery, Minimally invasive care, da Vinci surgical systems, Ion endoluminal system, Medical devices, Healthcare technology, Earnings report, Financial results, ISRG, Q4 2025, 2026 outlook